RxSight (RXST) Net Income towards Common Stockholders (2020 - 2026)

RxSight has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$15.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 93.94% year-over-year to -$15.9 million; the trailing twelve-month figure through Mar 2026 stood at -$46.6 million (down 5516.72% YoY), and the FY2025 full-year result was -$38.9 million, down 79377.55% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$15.9 million, down from -$9.2 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $51.1 million in Q4 2022, with the low at -$17.6 million in Q1 2022.
• Historically, Net Income towards Common Stockholders has averaged -$3.2 million across 5 years, with a median of -$9.8 million in 2025.
• The largest YoY upside for Net Income towards Common Stockholders was 425.03% in 2022 against a maximum downside of 158.57% in 2022.
• RxSight's Net Income towards Common Stockholders stood at $51.1 million in 2022, then declined by 22.93% to $39.4 million in 2023, then tumbled by 45.53% to $21.5 million in 2024, then tumbled by 142.63% to -$9.2 million in 2025, then sank by 73.56% to -$15.9 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$15.9 million (Q1 2026), -$9.2 million (Q4 2025), and -$9.8 million (Q3 2025), per Business Quant data.